Pfizer is far behind weight loss drug race despite pill trial, says Mizuho's Jared Holz

Pfizer is far behind weight loss drug race despite pill trial, says Mizuho's Jared HolzПодробнее

Pfizer steps up race for weight-loss drugПодробнее

Weight loss drug market is just beginning to take off, says Mizuho's Jared HolzПодробнее

'Overuse' is causing healthcare insurer headwinds, says Mizuho's Jared HolzПодробнее

Pfizer weight loss drug may be as effective as competitors: StudyПодробнее

Pfizer's weight loss pill may enter regulatory studies next year, says CEO Albert BourlaПодробнее

Pfizer stock drops after company picks twice-daily weight loss pill candidateПодробнее

People are 'scratching and clawing' for negative narrative around obesity drugs: Mizuho's Jared HolzПодробнее

Expectations for Pfizer have been low, says Mizuho's Jared Holz on weight-loss pill setbackПодробнее

Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared HolzПодробнее

Pill-ing It: The Breakthrough That's Changing Target Drug Delivery!Подробнее

Drugs for obesity are a massive market, says Mizuho's Jared HolzПодробнее

Novo Nordisk's STEP UP Trial: A Game-Changer in Obesity TreatmentПодробнее

Obesity drug enthusiasm can continue in 2024: Mizuho's Jared HolzПодробнее

Pfizer advances development of once-daily formulation of oral weight loss pillПодробнее

Obesity drug supply-demand imbalance is working in Novo Nordisk's favor: Mizuho's Jared HolzПодробнее

Pfizer weight-loss pills may work as well as shotsПодробнее

As weight loss drug demand soars, physician outlines effectiveness and potential downsidesПодробнее

Pfizer's weight-loss pill won't be in direct competition with Ozempic, says BMO's Evan SeigermanПодробнее

Pfizer stock rises on positive results from weight loss drug studyПодробнее